Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BTG

This article was originally published in The Gray Sheet

Executive Summary

British firm acquires U.S. and European rights from Oxford University scientists to noninvasive procedure for detecting fetal DNA in maternal serum or plasma samples. Technology likely will be applicable to prenatal screening for various inherited disorders, including Down's syndrome. Concept is based on a determination that an unborn baby's DNA can "find its way" into the mother's serum, and then DNA analysis can be performed to look for genetic disorders. BTG is searching for commercial partners
UsernamePublicRestriction

Register

MT014979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel